Skip to content

OS Therapies

2 viewers · 30d

Total raised

$11.6M

+$3.6M this year

4 filings since 2025 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $1.6M
ROUNDS
4
INVESTORS
9
FOUNDED
N/A
HQ
Grasonville, MD
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Ostherapies is a clinical-stage biotechnology company focused on developing immunotherapies that activate the patient's immune system to fight HER2-expressing cancers. The firm's primary objective is to advance its lead therapy through clinical trials, initially targeting osteosarcoma, a cancer that has not seen new treatments in over three decades.

What sets it apart

The company is pioneering a new treatment for osteosarcoma, addressing a critical unmet need that has persisted for more than 30 years, while also targeting other aggressive solid tumors.

Funding history

4 rounds
SAFE+2Jun 30, 2026
Form D
+$1.6M$11.6M total
SAFE+2Mar 4, 2026
Form D
+$2.0M$10.0M total
Equity+2Sep 2, 2025
Form D
+$3.8M$8.0M total
Equity+2Jun 23, 2025
Form D
+$4.2M$4.2M total

Products

1 tracked

Lead Immunotherapy Candidate

Clinical-Stage Immunotherapy

The company's flagship product is an immunotherapy drug currently in human clinical trials. It is engineered to activate the body's immune system to recognize and eliminate cancer cells that express the HER2 protein, with an initial indication for osteosarcoma and potential application across other solid tumors.

  • Novel immune activation mechanism
  • Targets HER2-expressing cancer cells
  • Addresses a significant treatment gap in osteosarcoma for both children and adults

Links

WebsiteSEC EDGAR filings